CVN424 150 mg

DRUG2 trials

Sponsors

Cerevance Beta, Inc., Cerevance

Conditions

Parkinson DiseaseParkinson's Disease

Phase 2

Early Parkinson's Disease Monotherapy With CVN424

CompletedNCT06006247

Cerevance Beta, Inc.Parkinson's Disease

Start: 2023-09-11End: 2025-02-13Updated: 2026-03-23

Phase 3

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Active, not recruitingNCT06553027

CerevanceParkinson Disease

Start: 2024-09-20End: 2026-08-01Target: 330Updated: 2026-04-17

Related Papers

CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.

2024-10-184 citations